Target validation of CD206 activators

CD206 激活剂的靶标验证

• 批准号: 10688947
• 负责人: Juan Marugan
• 金额: $ 25.96万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688947
• 关键词: Automobile Driving; Binding; Collaborations; Communities; Development; Disease; Extramural Activities; Fostering; General Population; Host Defense; Immune checkpoint inhibitor; Immunomodulators; Immunotherapy; In Vitro; Informatics; Interferometry; Link; Peptides; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phenotype; Process; Publications; Research; Research Personnel; Resources; Signal Transduction; Site; Surface; Translations; United States National Institutes of Health; Validation; Work; drug discovery; high throughput screening; human disease; improved; in vivo Model; inhibitor; macrophage; molecular modeling; novel; novel therapeutics; peptide analog; recruit; screening; small molecule; synthetic peptide; tumor

During this period, the collaborative team has worked to utilize microscale thermophoresis (MST) and biolayer interferometry (BLI) to probe binding and target engagement of CD206 inhibitors. Additionally, the team has identified novel CD206 activators through molecular modeling and medicinal chemistry efforts. These molecules are being extensively investigated and characterized using in vitro and in vivo models to define effects on macrophage phenotypes and anti-tumor activity, towards development of a novel immunotherapy.

在此期间，合作团队致力于利用微尺度热泳动（MST）和生物层干涉测量（BLI）来探测CD206抑制剂的结合和靶向作用。此外，该团队还通过分子建模和药物化学工作鉴定了新型 CD206 激活剂。 正在使用体外和体内模型对这些分子进行广泛研究和表征，以确定对巨噬细胞表型和抗肿瘤活性的影响，以开发新型免疫疗法。